ArticlePharmacological reports : PR2026
Association between elemental concentrations and chemotherapy-related acute adverse events in patients with nasopharyngeal carcinoma.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile environmental exposure to toxic elements, such as cadmium (Cd) and chromium (Cr), is known to impair general organ function, its specific impact on patients' tolerance to platinum (Pt)-based chemotherapy remains largely unexplored. This study aimed to determine whether pretreatment accumulation of specific trace elements is associated with the occurrence of acute adverse events (AEs) in patients with nasopharyngeal carcinoma (NPC) receiving platinum (Pt)-based chemotherapy.
methodsA single-center, prospective, longitudinal study was conducted on 140 patients with NPC. Elemental concentrations measured before the initiation of chemotherapy (hereafter referred to as "pretreatment concentrations") of 13 elements (arsenic (As), calcium (Ca), Cd, cobalt (Co), Cr, copper (Cu), mercury (Hg), magnesium (Mg), nickel (Ni), lead (Pb), platinum (Pt), selenium (Se), and zinc (Zn)) and acute AEs for each chemotherapy cycle were recorded. Elemental concentrations were measured in blood (B) and urine (U) using inductively coupled plasma mass spectrometry (ICP-MS). Univariate and multivariate logistic regression analyses were performed to evaluate the associations between element levels and chemotherapy-related acute adverse events (AEs).
resultsThe study enrolled 140 patients with stage II (n = 2, 1.4%), III (n = 76, 54.3%), and IVA (n = 62, 44.3%) NPC. Moderate positive correlations (Spearman's correlation coefficients ranging from 0.2 to 0.7, p < 0.05) were observed between the concentrations of individual elements (such as Cd, Pb, and Cr) measured in paired whole blood and urine samples. NPC patients with high urinary Cr, blood Cd, and urinary Pb concentrations were more likely to experience higher incidences of thrombocytopenia (5% vs. 23%, p = 0.002), hepatotoxicity (40% vs. 60%, p = 0.028), and dysglycemia (46% vs. 74%, p < 0.001), respectively. In the multivariate adjusted logistic regression, blood Cd (OR = 3.65, 95% CI 1.38-9.64; p = 0.009) and urinary Cr (OR = 3.34, 95% CI 1.60-19.87; p = 0.007) were identified as independent predictors of hepatotoxicity and thrombocytopenia in NPC patients receiving Pt-based chemotherapy.
conclusionsPretreatment elevation of specific elements, particularly blood Cd and urinary Cr, was independently associated with a significantly increased risk of chemotherapy-related acute AEs. Specifically, blood Cd and urinary Cr were independent predictors of hepatotoxicity and thrombocytopenia in NPC patients undergoing Pt-based chemotherapy.
Indexed as
Identifiers
42207470What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.